Welcome to our dedicated page for Enanta Pharmaceuticals SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enanta Pharmaceuticals, Inc. (ENTA) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered securities documents. As a Nasdaq Global Select Market issuer, Enanta uses these filings to report material events, financial results, capital markets transactions, and key clinical and corporate developments related to its small molecule virology and immunology programs.
Investors can review Form 8-K filings in which Enanta reports quarterly and annual financial results, including royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET and commentary on cash, cash equivalents and marketable securities. Other 8-Ks describe public offerings of common stock, such as underwriting agreements, expected net proceeds, and closing conditions for upsized offerings used to fund clinical trials, research, and general corporate purposes.
Filings also capture clinical and R&D milestones, for example the disclosure of positive topline data from the Phase 2b high-risk adult RSV study of zelicapavir, including symptom resolution, virology endpoints, and safety outcomes. Regulation FD 8-Ks may furnish slide presentations or press releases detailing these results. Additional 8-Ks document corporate governance and management changes, such as interim appointments to principal financial officer and principal accounting officer roles.
Enanta’s SEC reports further reference legal and intellectual property matters, including its announcement of a patent infringement suit in the Unified Patent Court of the European Union regarding European Patent No. EP 4 051 265 and Pfizer’s Paxlovid. Through Stock Titan, users can access these filings as they are posted to EDGAR, while AI-powered summaries help explain the implications of complex documents like 8-Ks, registration statements, and related exhibits. This allows readers to quickly understand how financings, clinical data disclosures, and legal actions may relate to Enanta’s RSV and immunology pipelines and its royalty-funded business model.
Enanta Pharmaceuticals reported temporary changes in its finance leadership. On August 26, 2025, the board named Harry R. Trout, III, the company’s Vice President of Finance, as interim principal financial officer and Kathleen (“Katie”) S. Capps, CPA, Executive Director, Accounting & Controller, as interim principal accounting officer. These appointments are explicitly described as interim while Chief Financial and Administrative Officer Paul J. Mellett is on a medical leave of absence and will continue until he is able to resume his roles. The company notes that Trout and Capps have long tenures in accounting and finance roles, will be eligible for standard indemnification agreements, and have not entered into any new material compensation or other arrangements in connection with these interim appointments. The filing also states there are no family relationships or related-party transactions involving either executive that require disclosure.
Enanta Pharmaceuticals reported stable royalty-driven revenue but continued operating losses while advancing multiple clinical and preclinical programs. Royalty revenue was $18.3 million for the quarter and $50.2 million for the nine months ended June 30, 2025. The company posted a net loss of $18.3 million for the quarter and $63.2 million for the nine months, and had an accumulated deficit of $386.2 million as of June 30, 2025.
Enanta held $204.1 million in cash, cash equivalents and short-term marketable securities and stated that these resources, together with retained royalty cash flows, are expected to fund operations into fiscal 2028. The company recorded a $147.7 million liability related to a $200.0 million royalty sale transaction and continues to recognize 100% of HCV royalties as revenue. Clinical updates include positive pediatric topline results for zelicapavir, completion of enrollment in a Phase 2b high-risk adult zelicapavir study (topline expected September 2025), positive Phase 2a challenge results for EDP-323, Phase 2 results for EDP-235, and progression of immunology programs (KIT and STAT6). The company has appealed a district court decision invalidating a patent asserted against Pfizer; appeal briefs have been filed.
Enanta Pharmaceuticals, Inc. filed a Form 8-K to report that it has announced its financial results for the fiscal quarter ended June 30, 2025. On August 11, 2025, the company issued a press release with these quarterly results and furnished that release as Exhibit 99.1. The filing is primarily administrative, directing readers to the press release for detailed financial information, and is signed on behalf of the company by President and Chief Executive Officer Jay R. Luly, Ph.D.
Scott T. Rottinghaus, identified in this filing as Chief Medical Officer of Enanta Pharmaceuticals (ENTA), reported a non-sale equity transaction dated 08/08/2025 in which 2,217 shares of ENTA common stock were forfeited to satisfy withholding taxes arising from the settlement of a portion of a restricted stock unit award granted on August 8, 2022. The filing lists a per-share amount of $6.99 associated with the transaction. Following the withholding forfeiture, the reporting person beneficially owns 22,590 shares of common stock directly. The Form 4 entry indicates this was an internal tax-withholding action rather than an open-market disposition and was executed by an attorney-in-fact on behalf of the reporting person.